Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry
Authors' conclusion
The use of DCBs in CTO recanalization is increasing and is associated with a reduction in the length of stents implanted, as well as a decrease in contrast volume and a lower rate of pericardial tamponade.
Study context
- Population
- CTO percutaneous coronary intervention (PCI) procedures in the European Registry of Chronic Total Occlusion (ERCTO), 2016–2023, 184 centresCTO PCIs, 184 centres
- Participants
- 40,449 procedures
- Exposure
- DCB vs no DCB in CTO PCI
- Outcome
- DCB use frequency
Methodological detailspropensity-score matched, multicentre
- Propensity-score matched
- Multicentre
Main finding
As reported in the abstract
Drug-coated balloons (DCBs) used overall
2,506
6.2%
DCB use in 2016
3.4%
n = 185 of 5,498
DCB use in 2023
14.9%
n = 705 of 4,722
Observational data: associations, not effects.
Further findings
Drug-eluting stent length · after propensity score matching
P < 0.001
95% CI DCB 42.7-45.7 mm · No DCB 56.7-59.5
Contrast volume · after propensity score matching
P = 0.005
95% CI DCB 198.1-206.7 mL · No DCB 206.8-216.4 mL
Safety
In-hospital pericardial tamponade
P = 0.006
In-hospital pericardial tamponade
- In-hospital complications infrequent
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Summarised from the published abstract; every number is checked against it